Medpace Holdings Inc (MEDP) Shares Sold by MetLife Investment Advisors LLC
MetLife Investment Advisors LLC lowered its stake in shares of Medpace Holdings Inc (NASDAQ:MEDP) by 36.1% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 9,844 shares of the company’s stock after selling 5,569 shares during the quarter. MetLife Investment Advisors LLC’s holdings in Medpace were worth $521,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors also recently bought and sold shares of the company. LS Investment Advisors LLC acquired a new position in shares of Medpace during the 4th quarter valued at about $46,000. SHANDA ASSET MANAGEMENT HOLDINGS Ltd acquired a new position in shares of Medpace during the 4th quarter valued at about $87,000. State of Alaska Department of Revenue acquired a new position in shares of Medpace during the 4th quarter valued at about $92,000. NumerixS Investment Technologies Inc acquired a new position in shares of Medpace during the 4th quarter valued at about $119,000. Finally, We Are One Seven LLC acquired a new position in shares of Medpace during the 4th quarter valued at about $130,000. 83.17% of the stock is owned by institutional investors.
MEDP has been the subject of a number of research analyst reports. BidaskClub downgraded shares of Medpace from a “strong-buy” rating to a “buy” rating in a research note on Friday, February 8th. ValuEngine raised shares of Medpace from a “hold” rating to a “buy” rating in a research report on Thursday, January 10th. TheStreet downgraded shares of Medpace from a “b” rating to a “c” rating in a research report on Friday, March 22nd. Zacks Investment Research downgraded shares of Medpace from a “buy” rating to a “hold” rating in a research report on Wednesday, January 9th. Finally, Wolfe Research initiated coverage on shares of Medpace in a research report on Tuesday, April 2nd. They set an “outperform” rating for the company. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $51.50.
MEDP opened at $59.99 on Thursday. The company has a market cap of $2.15 billion, a P/E ratio of 23.16, a price-to-earnings-growth ratio of 1.87 and a beta of 1.62. Medpace Holdings Inc has a 1 year low of $35.00 and a 1 year high of $71.66. The company has a debt-to-equity ratio of 0.18, a current ratio of 0.69 and a quick ratio of 0.69.
Medpace (NASDAQ:MEDP) last posted its earnings results on Monday, February 25th. The company reported $0.76 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.69 by $0.07. The firm had revenue of $192.12 million during the quarter, compared to the consensus estimate of $184.66 million. Medpace had a net margin of 11.27% and a return on equity of 17.66%. The company’s revenue was up 70.5% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.39 EPS. On average, analysts expect that Medpace Holdings Inc will post 2.64 earnings per share for the current year.
Medpace Holdings, Inc, a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in a range of therapeutic areas.
Read More: Blockchain
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.